JP2014521653A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014521653A5 JP2014521653A5 JP2014523015A JP2014523015A JP2014521653A5 JP 2014521653 A5 JP2014521653 A5 JP 2014521653A5 JP 2014523015 A JP2014523015 A JP 2014523015A JP 2014523015 A JP2014523015 A JP 2014523015A JP 2014521653 A5 JP2014521653 A5 JP 2014521653A5
- Authority
- JP
- Japan
- Prior art keywords
- nitrogen
- sulfur
- oxygen
- ring
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 44
- 229910052757 nitrogen Inorganic materials 0.000 claims 27
- 229910052760 oxygen Inorganic materials 0.000 claims 27
- 229910052717 sulfur Inorganic materials 0.000 claims 27
- 239000001301 oxygen Substances 0.000 claims 26
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 26
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 26
- 239000011593 sulfur Substances 0.000 claims 26
- 125000005842 heteroatoms Chemical group 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 22
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 9
- 125000004429 atoms Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- 239000011780 sodium chloride Substances 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000001931 aliphatic group Chemical group 0.000 claims 4
- 125000002619 bicyclic group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- -1 aryl carbon Chemical compound 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims 3
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 241000162682 Heterogen Species 0.000 claims 2
- 102100014004 XPO1 Human genes 0.000 claims 2
- 108091004173 exportin 1 protein Proteins 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- RCDZDLFYRJZSRK-ZHACJKMWSA-N (E)-3-[3-(3-chlorophenyl)-1,2,4-triazol-1-yl]-N-methyl-N-phenylprop-2-enamide Chemical compound C=1C=CC=CC=1N(C)C(=O)\C=C\N(N=1)C=NC=1C1=CC=CC(Cl)=C1 RCDZDLFYRJZSRK-ZHACJKMWSA-N 0.000 claims 1
- RUDSDOHVAFYBTM-MDZDMXLPSA-N (E)-3-[3-(3-chlorophenyl)-1,2,4-triazol-1-yl]-N-phenylprop-2-enamide Chemical compound ClC1=CC=CC(C2=NN(\C=C\C(=O)NC=3C=CC=CC=3)C=N2)=C1 RUDSDOHVAFYBTM-MDZDMXLPSA-N 0.000 claims 1
- KLSWUGZLBXALSD-IHWYPQMZSA-N (Z)-1-(3,3-difluoroazetidin-1-yl)-3-[3-[3-methoxy-5-(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]prop-2-en-1-one Chemical compound FC(F)(F)C1=CC(OC)=CC(C2=NN(\C=C/C(=O)N3CC(F)(F)C3)C=N2)=C1 KLSWUGZLBXALSD-IHWYPQMZSA-N 0.000 claims 1
- NTQHQDQUJOAGJT-YVMONPNESA-N (Z)-1-(azetidin-1-yl)-3-[3-(3-chlorophenyl)-1,2,4-triazol-1-yl]prop-2-en-1-one Chemical compound ClC1=CC=CC(C2=NN(\C=C/C(=O)N3CCC3)C=N2)=C1 NTQHQDQUJOAGJT-YVMONPNESA-N 0.000 claims 1
- BUPMTQXOUNEYNB-PLNGDYQASA-N (Z)-3-[3-(3-chlorophenyl)-1,2,4-triazol-1-yl]-1-(3,3-difluoroazetidin-1-yl)prop-2-en-1-one Chemical compound C1C(F)(F)CN1C(=O)\C=C/N1N=C(C=2C=C(Cl)C=CC=2)N=C1 BUPMTQXOUNEYNB-PLNGDYQASA-N 0.000 claims 1
- VEOYQBARQJOBNI-HJWRWDBZSA-N (Z)-3-[3-(3-chlorophenyl)-1,2,4-triazol-1-yl]-N-cyclopentylprop-2-enamide Chemical compound ClC1=CC=CC(C2=NN(\C=C/C(=O)NC3CCCC3)C=N2)=C1 VEOYQBARQJOBNI-HJWRWDBZSA-N 0.000 claims 1
- CWTQASMKSDZRBL-SREVYHEPSA-N (Z)-3-[3-(3-chlorophenyl)-1,2,4-triazol-1-yl]-N-fluoro-N-propan-2-ylprop-2-enamide Chemical compound CC(C)N(F)C(=O)\C=C/N1C=NC(C=2C=C(Cl)C=CC=2)=N1 CWTQASMKSDZRBL-SREVYHEPSA-N 0.000 claims 1
- VGZKRZFYTIDSBR-FPLPWBNLSA-N (Z)-3-[3-(3-chlorophenyl)-1,2,4-triazol-1-yl]-N-methyl-N-propan-2-ylprop-2-enamide Chemical compound CC(C)N(C)C(=O)\C=C/N1C=NC(C=2C=C(Cl)C=CC=2)=N1 VGZKRZFYTIDSBR-FPLPWBNLSA-N 0.000 claims 1
- SEYJUEYOXZWIQG-KTKRTIGZSA-N (Z)-3-[3-(3-chlorophenyl)-1H-1,2,4-triazol-5-yl]-N-phenylprop-2-enamide Chemical compound ClC1=CC=CC(C=2NC(\C=C/C(=O)NC=3C=CC=CC=3)=NN=2)=C1 SEYJUEYOXZWIQG-KTKRTIGZSA-N 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- LBNWRDCVNGUTBP-MDZDMXLPSA-M C1=CC(OC)=CC=C1[N-]C(=O)\C=C\N1N=C(C=2C=C(Cl)C=CC=2)N=C1 Chemical compound C1=CC(OC)=CC=C1[N-]C(=O)\C=C\N1N=C(C=2C=C(Cl)C=CC=2)N=C1 LBNWRDCVNGUTBP-MDZDMXLPSA-M 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010038428 Renal disease Diseases 0.000 claims 1
- 206010047461 Viral infection Diseases 0.000 claims 1
- 208000001756 Virus Disease Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000240 adjuvant Effects 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 200000000028 growth disorder Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 200000000018 inflammatory disease Diseases 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 230000001613 neoplastic Effects 0.000 claims 1
- 150000002829 nitrogen Chemical group 0.000 claims 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 230000017613 viral reproduction Effects 0.000 claims 1
- 0 C*(C)N1CCNCC1 Chemical compound C*(C)N1CCNCC1 0.000 description 1
- WQEBYNUXWYRLCB-UHFFFAOYSA-N CCN1CC2(CNC2)CC1 Chemical compound CCN1CC2(CNC2)CC1 WQEBYNUXWYRLCB-UHFFFAOYSA-N 0.000 description 1
- YSRSYYHGSQMAFV-UHFFFAOYSA-N CN(CC12)CC1C2N Chemical compound CN(CC12)CC1C2N YSRSYYHGSQMAFV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161513432P | 2011-07-29 | 2011-07-29 | |
US201161513428P | 2011-07-29 | 2011-07-29 | |
US61/513,432 | 2011-07-29 | ||
US61/513,428 | 2011-07-29 | ||
US201261653588P | 2012-05-31 | 2012-05-31 | |
US61/653,588 | 2012-05-31 | ||
PCT/US2012/048368 WO2013019561A1 (en) | 2011-07-29 | 2012-07-26 | Nuclear transport modulators and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016176098A Division JP2016199604A (ja) | 2011-07-29 | 2016-09-09 | 核内輸送調節因子およびその使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014521653A JP2014521653A (ja) | 2014-08-28 |
JP2014521653A5 true JP2014521653A5 (US07794700-20100914-C00152.png) | 2015-08-20 |
JP6006794B2 JP6006794B2 (ja) | 2016-10-12 |
Family
ID=46682903
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014523015A Active JP6006794B2 (ja) | 2011-07-29 | 2012-07-26 | 核内輸送調節因子およびその使用 |
JP2016176098A Withdrawn JP2016199604A (ja) | 2011-07-29 | 2016-09-09 | 核内輸送調節因子およびその使用 |
JP2018006773A Active JP6752235B2 (ja) | 2011-07-29 | 2018-01-18 | 核内輸送調節因子およびその使用 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016176098A Withdrawn JP2016199604A (ja) | 2011-07-29 | 2016-09-09 | 核内輸送調節因子およびその使用 |
JP2018006773A Active JP6752235B2 (ja) | 2011-07-29 | 2018-01-18 | 核内輸送調節因子およびその使用 |
Country Status (16)
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011109799A1 (en) | 2010-03-05 | 2011-09-09 | Karyopharm Therapeutics, Inc. | Nuclear transport modulatiors and uses thereof |
CN103402359B (zh) | 2011-01-17 | 2016-08-24 | 卡尔约药物治疗公司 | 含烯烃核运输调节剂及其用途 |
CA2842364A1 (en) * | 2011-07-29 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
DK3333164T3 (da) | 2011-07-29 | 2023-09-18 | Karyopharm Therapeutics Inc | Hydrazide containing nuclear transport modulators and uses thereof |
LT2858991T (lt) | 2012-05-09 | 2018-11-26 | Biogen Ma Inc. | Branduolinio transporto moduliatoriai ir jų panaudojimas |
JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
EP2968278B8 (en) | 2013-03-15 | 2019-05-22 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
WO2014205393A1 (en) * | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
KR102545732B1 (ko) * | 2013-06-21 | 2023-06-20 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 핵수송 조절인자 및 이의 용도 |
TN2016000022A1 (en) | 2013-07-18 | 2017-07-05 | Novartis Ag | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core |
US9469650B2 (en) | 2013-11-08 | 2016-10-18 | Board Of Trustees Of The University Of Arkansas | Melampomagnolide B derivatives |
US9487536B2 (en) | 2013-11-08 | 2016-11-08 | Board Of Trustees Of The University Of Arkansas | Melampomagnolide B derivatives |
US9861615B2 (en) * | 2013-11-28 | 2018-01-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of beta-thalassemias |
WO2015138934A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
US9790219B2 (en) | 2014-03-13 | 2017-10-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
WO2015196071A1 (en) | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
CN107072992B (zh) | 2014-08-15 | 2020-03-10 | 卡尔约药物治疗公司 | 赛灵克斯的多晶型物 |
US9981990B2 (en) | 2014-12-03 | 2018-05-29 | Bioventures, Llc | Melampomagnolide B dimers |
MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
CA2971850A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
US10738011B2 (en) | 2014-12-23 | 2020-08-11 | Proteostasis Therapeutics, Inc. | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
US10344023B2 (en) | 2014-12-23 | 2019-07-09 | Proteostasis Therapeutics, Inc. | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
WO2017019589A1 (en) | 2015-07-24 | 2017-02-02 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
ES2930848T3 (es) | 2015-09-23 | 2022-12-22 | Xwpharma Ltd | Profármacos de ácido gamma-hidroxibutírico, composiciones y usos de los mismos |
SG11201802798WA (en) | 2015-10-06 | 2018-05-30 | Proteostasis Therapeutics Inc | Compounds, compositions, and methods for modulating cftr |
CN105384673B (zh) * | 2015-11-09 | 2017-11-14 | 南京富润凯德生物医药有限公司 | 3‑氟代‑氮杂环丁烷衍生物的合成方法 |
WO2017117535A1 (en) * | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
WO2017117529A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
EP3407885A4 (en) * | 2016-01-29 | 2019-06-19 | BioVentures, LLC | TRIAZOLE DERIVATIVES OF MELAMPOMAGNOLIDE B AND METHODS OF USE THEREOF |
AU2017248253B2 (en) | 2016-04-07 | 2021-07-29 | Proteostasis Therapeutics, Inc. | Silicone atoms containing ivacaftor analogues |
JP2019521109A (ja) * | 2016-06-08 | 2019-07-25 | グラクソスミスクライン、インテレクチュアル、プロパテ | 化学化合物 |
AU2017280206A1 (en) | 2016-06-21 | 2019-01-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
EP3512515A1 (en) | 2016-09-16 | 2019-07-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of systemic mastocytosis |
WO2018098472A1 (en) | 2016-11-28 | 2018-05-31 | Karyopharm Therapeutics Inc. | Crm1 inhibitors for treating epilepsy |
CN106831731B (zh) * | 2017-01-17 | 2019-11-08 | 广州市闻皓生物科技有限公司 | 一种Selinexor原料药的合成方法 |
CN110709386B (zh) | 2017-03-30 | 2022-06-07 | 凯瑞康宁生物工程(武汉)有限公司 | 双环杂芳基衍生物及其制备与用途 |
IL275968B2 (en) | 2018-01-10 | 2024-07-01 | Xwpharma Ltd | Ketamine prodrugs, preparations containing them and their uses |
WO2019232724A1 (en) | 2018-06-06 | 2019-12-12 | Xw Laboratories, Inc. | Compounds as nuclear transport modulators and uses thereof |
CN110592141B (zh) * | 2018-06-13 | 2023-07-07 | 中国科学院上海有机化学研究所 | 用于调控基因编辑效率的化合物及其应用 |
CN112004802B (zh) | 2018-09-30 | 2021-12-28 | 凯瑞康宁生物工程(武汉)有限公司 | 作为神经元组胺受体-3拮抗剂的化合物及其用途 |
CN111606890A (zh) * | 2019-02-26 | 2020-09-01 | 微境生物医药科技(上海)有限公司 | 含丙烯酰基的核转运调节剂及其用途 |
JP2020141256A (ja) | 2019-02-28 | 2020-09-03 | ソニーセミコンダクタソリューションズ株式会社 | 復調回路、復調方法、送信装置 |
EP4077262B1 (en) | 2019-12-20 | 2024-07-24 | XWPharma Ltd. | Methods of synthesizing 4-valyloxybutyric acid |
EP4167966A1 (en) | 2020-06-18 | 2023-04-26 | XWPharma Ltd. | Pharmaceutical granulations of water-soluble active pharmaceutical ingredients |
EP4167971A1 (en) | 2020-06-18 | 2023-04-26 | XWPharma Ltd. | Controlled release granulations of water-soluble active pharmaceutical ingredients |
US11896573B2 (en) | 2020-07-24 | 2024-02-13 | XWPharma Ltd. | Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative |
WO2022076466A1 (en) | 2020-10-05 | 2022-04-14 | XWPharma Ltd. | Modified release compositions of a gamma-hydroxybutyric acid derivative |
WO2022143779A1 (zh) * | 2020-12-29 | 2022-07-07 | 南京明德新药研发有限公司 | 含烯基类化合物及其应用 |
WO2022198033A1 (en) | 2021-03-19 | 2022-09-22 | XWPharma Ltd. | Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative |
CN117881394A (zh) | 2021-08-13 | 2024-04-12 | 凯瑞康宁生物工程(武汉)有限公司 | 氯胺酮衍生物的药物组合物和口服剂型 |
WO2024175804A1 (en) * | 2023-02-24 | 2024-08-29 | Katholieke Universiteit Leuven | Nuclear transport modulators |
CN116514773A (zh) * | 2023-04-24 | 2023-08-01 | 重庆汉佩生物科技有限公司 | 一种Verdinexor(KPT-335)及其盐酸盐的合成方法 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR840000529A (ko) * | 1981-07-07 | 1984-02-25 | 콘스탄틴 루이스 클레멘트 | 인돌 유도체의 제조방법 |
US4778796A (en) * | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
JP3111321B2 (ja) * | 1990-02-23 | 2000-11-20 | 武田薬品工業株式会社 | 縮合チアゾール化合物 |
IL97249A (en) * | 1990-02-23 | 1995-01-24 | Takeda Chemical Industries Ltd | Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or |
US5541213A (en) * | 1993-06-24 | 1996-07-30 | Eisai Co., Ltd. | Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility |
US5468353A (en) * | 1994-05-05 | 1995-11-21 | Minnesota Mining And Manufacturing Company | Mist suppressant for solvent extraction metal electrowinning |
CN1088062C (zh) * | 1994-11-23 | 2002-07-24 | 纽罗根公司 | 某些4-氨基甲基-2-取代的咪唑衍生物2-氨基甲基-4-取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体 |
US20030018025A1 (en) * | 1995-06-07 | 2003-01-23 | Neurogen Corporation, Corporation Of The State Of Delaware | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands |
WO1997015567A1 (de) * | 1995-10-20 | 1997-05-01 | Dr. Karl Thomae Gmbh | 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung |
CN1088711C (zh) * | 1996-04-04 | 2002-08-07 | 盐野义制药株式会社 | 头孢烯化合物及含该化合物的医药 |
EP1360901A1 (en) | 1996-04-25 | 2003-11-12 | Nissan Chemical Industries, Limited | 2,3-cyclic substituted derivatives of 3-hydroxyacrolein and 3-hydroxyacrylic acid as pesticides |
US5994398A (en) * | 1996-12-11 | 1999-11-30 | Elan Pharmaceuticals, Inc. | Arylsulfonamides as phospholipase A2 inhibitors |
JP4416198B2 (ja) * | 1997-12-19 | 2010-02-17 | 武田薬品工業株式会社 | アニリド誘導体、その製造法および用途 |
WO1999050264A1 (fr) * | 1998-03-30 | 1999-10-07 | Kyowa Hakko Kogyo Co., Ltd. | Derives de quinazoline |
AR029803A1 (es) * | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
CA2423868C (en) * | 2000-09-29 | 2011-06-07 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
BR0212510A (pt) * | 2001-09-14 | 2004-08-24 | Methylgene Inc | Inibidor de histona desacetilase, composto e composição |
WO2004037248A2 (en) * | 2002-10-24 | 2004-05-06 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
DE10250743A1 (de) * | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
EP1556032A1 (en) * | 2002-11-01 | 2005-07-27 | Takeda Pharmaceutical Company Limited | Agent for preventing or treating neuropathy |
JP4145230B2 (ja) * | 2002-11-01 | 2008-09-03 | 武田薬品工業株式会社 | 神経障害の予防・治療剤 |
WO2004043925A2 (en) * | 2002-11-08 | 2004-05-27 | Neurogen Corporation | 3-substituted-6-aryl pyridined as ligands of c5a receptors |
CA2512886A1 (en) * | 2003-02-28 | 2004-09-10 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
US7667041B2 (en) * | 2004-05-26 | 2010-02-23 | Eisai R&D Management Co., Ltd. | Cinnamide compound |
JPWO2006016637A1 (ja) * | 2004-08-11 | 2008-05-01 | 杏林製薬株式会社 | 新規環状アミノ安息香酸誘導体 |
WO2006088246A1 (ja) * | 2005-02-18 | 2006-08-24 | Takeda Pharmaceutical Company Limited | Gpr34受容体機能調節剤 |
MY153720A (en) | 2005-11-15 | 2015-03-13 | Otsuka Pharma Co Ltd | Oxazole compound and pharmaceutical composition |
EA016464B1 (ru) | 2006-03-09 | 2012-05-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Полициклические производные арилимидазола |
ES2452820T3 (es) * | 2006-04-07 | 2014-04-02 | Methylgene, Inc. | Derivados de benzamida como inhibidores de histona desacetilasa |
CN101466687B (zh) | 2006-04-18 | 2012-04-11 | 日本化学医药株式会社 | 过氧化物酶体增殖剂激活受体δ的激活剂 |
EP2030974B1 (en) | 2006-06-13 | 2016-02-17 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Thiazole non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents |
EP2054411B1 (en) * | 2006-07-27 | 2014-08-20 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
ES2376668T3 (es) * | 2006-09-05 | 2012-03-15 | Kyowa Hakko Kirin Co., Ltd. | Derivado de imidazol. |
EP1942104A1 (en) * | 2006-12-20 | 2008-07-09 | sanofi-aventis | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals |
EP1939180A1 (en) | 2006-12-20 | 2008-07-02 | sanofi-aventis | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase |
WO2011109799A1 (en) * | 2010-03-05 | 2011-09-09 | Karyopharm Therapeutics, Inc. | Nuclear transport modulatiors and uses thereof |
CN103402359B (zh) | 2011-01-17 | 2016-08-24 | 卡尔约药物治疗公司 | 含烯烃核运输调节剂及其用途 |
US9152882B2 (en) * | 2011-06-17 | 2015-10-06 | Microsoft Technology Licensing, Llc. | Location-aided recognition |
DK3333164T3 (da) | 2011-07-29 | 2023-09-18 | Karyopharm Therapeutics Inc | Hydrazide containing nuclear transport modulators and uses thereof |
CA2842364A1 (en) * | 2011-07-29 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
LT2858991T (lt) | 2012-05-09 | 2018-11-26 | Biogen Ma Inc. | Branduolinio transporto moduliatoriai ir jų panaudojimas |
EP2968278B8 (en) * | 2013-03-15 | 2019-05-22 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
US20160016916A1 (en) | 2013-03-15 | 2016-01-21 | Karyopharm Therapeutics Inc. | Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof |
WO2014205393A1 (en) | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
KR102545732B1 (ko) | 2013-06-21 | 2023-06-20 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 핵수송 조절인자 및 이의 용도 |
-
2012
- 2012-07-26 CA CA2842364A patent/CA2842364A1/en not_active Abandoned
- 2012-07-26 EP EP12748083.8A patent/EP2736883B1/en active Active
- 2012-07-26 CN CN201280047930.1A patent/CN103842340B/zh active Active
- 2012-07-26 US US14/235,342 patent/US9428490B2/en active Active
- 2012-07-26 WO PCT/US2012/048368 patent/WO2013019561A1/en active Application Filing
- 2012-07-26 BR BR112014001933A patent/BR112014001933A2/pt not_active Application Discontinuation
- 2012-07-26 KR KR1020147005649A patent/KR102022715B1/ko active IP Right Grant
- 2012-07-26 PE PE2014000137A patent/PE20141003A1/es active IP Right Grant
- 2012-07-26 JP JP2014523015A patent/JP6006794B2/ja active Active
- 2012-07-26 SG SG10201609097PA patent/SG10201609097PA/en unknown
- 2012-07-26 MX MX2014001180A patent/MX350442B/es active IP Right Grant
- 2012-07-26 EA EA201490406A patent/EA201490406A1/ru unknown
- 2012-07-26 UA UAA201401884A patent/UA117902C2/uk unknown
-
2014
- 2014-01-29 CL CL2014000224A patent/CL2014000224A1/es unknown
- 2014-11-27 HK HK14111985.8A patent/HK1198478A1/xx unknown
-
2015
- 2015-05-11 CL CL2015001259A patent/CL2015001259A1/es unknown
-
2016
- 2016-07-22 US US15/217,514 patent/US20170137430A1/en not_active Abandoned
- 2016-08-11 AU AU2016213805A patent/AU2016213805A1/en not_active Abandoned
- 2016-09-09 JP JP2016176098A patent/JP2016199604A/ja not_active Withdrawn
-
2018
- 2018-01-18 JP JP2018006773A patent/JP6752235B2/ja active Active
- 2018-06-14 AU AU2018204256A patent/AU2018204256A1/en not_active Abandoned
-
2019
- 2019-04-25 US US16/394,986 patent/US20200087313A1/en not_active Abandoned
-
2021
- 2021-05-04 US US17/307,656 patent/US20220056038A1/en not_active Abandoned